|Mr. Anthony J. Hunt||Chief Exec. Officer, Pres, Director and Member of Scientific Advisory Board||903.25k||N/A||53|
|Mr. Jon K. Snodgres||Chief Financial Officer and Sec.||523.35k||N/A||51|
|Dr. Howard Benjamin Ph.D.||VP of Bus. Devel.||411.99k||177.49k||57|
|Mr. Steve Curran||VP of Global Operations||N/A||N/A||N/A|
|Ms. Sondra S. Newman||Sr. Director Investor Relations||N/A||N/A||N/A|
Repligen Corporation, a bioprocessing company, focuses on the development, production, and commercialization of products used in the production of antibody-based therapeutics, recombinant proteins, and vaccines worldwide. It manufactures various forms of Protein A, a critical component used to purify antibody-based drugs. The company also supplies alternating tangential flow system filtration devices and protein cell culture supplements that are used in clinical and commercial stage manufacturing to enhance biologic drug yields. In addition, it manufactures and sells OPUS pre-packed chromatography columns, which are used in the purification of clinical-stage biologics; and tangential flow filtration cassettes that are used to concentrate clinical and commercial stage biologic drugs. Further, the company has a portfolio of therapeutic product candidates, which include histone deacetylase inhibitor for the treatment of Friedreichs ataxia disease; and RG1068, a synthetic human hormone developed as a novel imaging agent for the detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and other pancreatic diseases. The company sells its bioprocessing products directly and through distributors to various life sciences companies, biopharmaceutical companies, and contract manufacturers. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.
Repligen Corporation’s ISS Governance QualityScore as of September 1, 2017 is 1. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 1; Compensation: 4.